Mutations of the HFE gene in patients with hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 98, Issue 2, 2003, Pages 442-447

  Cauza, Edmund ^a   Peck Radosavljevic, Markus ^a   Ulrich Pur, Herbert ^a   Datz, Christian ^a   Gschwantler, Michael ^a   Schöniger Hekele, Maximilian ^a   Hackl, Franz ^a   Polli, Claudia ^a   Rasoul Rockenschaub, Susanne ^a   Müller, Christian ^a   Wrba, Friedrich ^a   Gangl, Alfred ^a   Ferenci, Peter ^a  

^a Department of Internal Medicine IV ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HETEROZYGOTE; HFE GENE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037285572     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07222.x     Document Type: Article

References (48)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
2. Cancer statistics 1994. CA Cancer J Clin 1994;44:18.
3. Kew MC. Hepatic tumors and cysts. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds Sleisinger and Fordtran: Gastrointestinal and liver diseases: Pathophysiology/diagnosis/management. Philadelphia: WB Saunders, 1998:1364-87.
4. Ferenci P, Dragosics B, Marosi L, et al. Relative incidence of primary liver cancer in cirrhosis in Austria - etiological considerations. Liver 1984;4:7-14.
5. Mandishona E, MacPhail AP, Gordeuk VR, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-6.
6. Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of multiple-cause mortality data. Ann Intern Med 1998;129:946-53.
7. Stal P, Wang GS, Olsson JM, et al. Effects of dietary iron overload on progression in chemical hepatocarcinogenesis. Liver 1999;19:326-34.
8. Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: A clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104:228-34.
9. Grando-Lemaire V, Guettier C, Chevret S, et al. Hepatocellular carcinoma without cirrhosis in the West: Epidemiological factors and histopathology of the non-tumorous liver. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:508-13.
10. Goh J, Callagy G, McEntee G, et al. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: Three case reports and review of literature. Eur J Gastroenterol Hepatol 1999;11:915-9.
11. Willis G, Wimperis JZ, Lonsdale R, et al. Haemochromatosis gene mutation in hepatocellular cancer. Lancet 1997;350: 565-6.
12. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
13. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:339-408.
14. Datz C, Lalloz M, Vogel W, et al. Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic hemochromatosis. J Hepatol 1997;27:773-9.
15. Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 1999;116:1409-12.
16. Piperno A, Arosio C, Fossati L, et al. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000;119:441-5.
17. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild form of hemochromatosis. Blood 1999;93:2502-5.
18. Blanc JF, De Ledinghen V, Bernard PH, et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000;32:862-6.
19. Fargion S, Stazi MA, Fracanzani AL, et al. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 2001;27:505-11.
20. Pirisi M, Toniutto P, Uzzau A, et al. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 2000;89:297-302.
21. Racchi O, Mangerini R, Rapezzi D, et al. Mutations of the HFE gene and the risk of hepatocellular carcinoma. Blood Cells Mol Dis 1999;25:350-3.
22. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-34.
23. Edmonson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
24. Rowe JW, Wands JR, Mezey E, et al. Familial hemochromatosis: Characteristics of the precirrhotic stage in precirrhotic stage in a large kindred. Medicine (Baltimore) 1977;56:197-211.
25. DiBisceglie AM, Axiotis CA, Hoofnagle JH, et al. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-13.
26. Searle JW, Kerr JFR, Halliday JW, et al. Iron storage disease. In: McSween RNM, Anthony PP, Scheuer PJ, eds. Pathology of the liver, 2nd ed. New York: Churchill Livingstone, 1989:181-201.
27. Kaserer K, Fiedler R, Steindl P, et al. Liver biopsy is a useful predictor of response to interferon-therapy in chronic hepatitis C. Histopathology 1998;32:454-61.
28. Ahlbom A. Biostatistics for epidemiologists. Boca Raton: Lewis Publisher, 1993.
29. Fargion S, Fracanzani AL, Pipemo A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994;20:1426-31.
30. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-51.
31. Shaheen NJ, Bacon BR, Grimm IS. Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation. Hepatology 1998;28:526-9.
32. Ludwig J, Hashimoto E, Porayko MK, et al. Hemosiderosis in cirrhosis: A study of 447 native livers. Gastroenterology 1997; 112:882-8.
33. Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: At the crossroads. Gastroenterology 1999;116:193-207.
34. Datz C, Haas T, Rinner H, et al. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: A protective role against iron deficiency? Clin Chem 1998;44:2429-32.
35. Weiss W, Hanak H. Primary liver carcinoma in Austria. In: Remmer H, Bannasch P, Bolt HM, Popper H, eds. Primary liver tumors. Lancaster: MTP Press, 1978:145-7.
36. Müller CH, Schoeninger-Hekele M, Kutilek M, et al. Hepatocellular carcinoma in Austria: Aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000;12:941-8.
37. Alanen KW, Chakrabarti S, Rawlins JJ, et al. Prevalence of the C282Y mutation of the hemochromatosis gene in liver transplant recipients and donors. Hepatology 1999;30:665-9.
38. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the "HFE" gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-9.
39. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-8.
40. Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-84.
41. Fargion S, Valenti L, Dongiovanni P, et al. Tumor necrosis factor-promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001;97:3707-12.
42. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Lancet 1997;349:825-32.
43. Kew MD. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: Occurrence in non cirrhotic patients. Hepatology 1990;11:1086-7.
44. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998;28(suppl 1):8-13.
45. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species: Its mechanism and measurement in mammalian systems. FEBS Lett 1991;281:9-19.
46. Donnelly ET, McClure N, Lewis SE. The effect of ascorbate and alpha-tocopherol supplementation in vitro on DNA integrity and hydrogen peroxide-induced DNA damage in human spermatozoa. Mutagenesis 1999;14:505-12.
47. Breen AP, Murphy JA. Reactions of oxyl radicles with DNA. Free Radic Biol Med 1995;18:1033-77.
48. Vautier G, Bomford AB, Portmann BC, et al. p53 Mutations in British patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 1999;117:154-60.